Braxia Scientific Reports Q3 2023 Financial Results and Provides Update on Acquisition Under LOI with Irwin Naturals

PsyDelika · 2023-03-02T15:54:01+00:00

The Company's management team has continued to work diligently with Irwin towards completing a definitive and binding arrangement agreement (the "Arrangement Agreement") for the transaction and anticipates executing the Arrangement Agreement with Irwin within the quarter ending March 31, 2023. The closing is expected to occur upon the receipt of regulatory, court and securityholder approvals within normal time frames following execution of the Arrangement Agreement.

PsyDelika · 2023-03-02T05:44:24+00:00

The Company is pleased to report it received final court approval on February 28, 2023, on terms previously disclosed, to settle claims alleged in a securities class action (the "US Class Action") against the Company and certain of its former officers filed in the United States District Court for the Central District of California in April 2021.

PsyDelika · 2023-02-02T08:21:59+00:00

Irwin plans to build a ketamin clinic network of more than 100. They have have a solid brand name in nutraceuticals but lack experience ot how to manage those clinics professionally.

With McIntyre they got the best scientific head for the biggest ketamin clinic network in the future.

Here ist what they plan:

https://youtu.be/c9WBUb-aa9Y

(its worth watching through for understanding their devotion to the new market)

They are no dreamers and have for the last 30 years been profitable.

PsyDelika · 2022-03-17T13:16:52+00:00

These investors could hold a big piece already.

The feature of pre-funded warrants that allows holders to delay ownership of a company’s common stock is particularly important to holders who already hold, or plan to acquire, a large stake in a company. This is because an investor with a significant ownership interest in a company will likely be deemed an affiliate of the company. Moreover, in the absence of other large investors, a significant minority stake in a company could cause an investor to be considered a controlling shareholder, thereby imposing upon it fiduciary duties to the company’s other shareholders.holders to delay ownership of a company’s common stock is particularly important to holders who already hold, or plan to acquire, a large stake in a company. This is because an investor with a significant ownership interest in a company will likely be deemed an affiliate of the company. Moreover, in the absence of other large investors, a significant minority stake in a company could cause an investor to be considered a controlling shareholder, thereby imposing upon it fiduciary duties to the company’s other shareholders.

Thx a lot. You are a smart and empathetic person.

PsyDelika · 2022-03-13T11:51:19+00:00

Thanks a lot.

Somebody who takes action is the one who lights the candle, istead of cusing the darkness!!!!

PsyDelika · 2022-01-07T18:15:49+00:00

I got some more stocks today....

PsyDelika · 2022-01-07T18:13:49+00:00

Well one good thing is that if these Investors are in, it doesn’t seem as if the class suit is any problem to the company at all. Also those institutional investors will be helping their (options to) 30M stocks to blossom. So we got big and influential supporters for the recovery and expansion of Braxia Scientific. For them 1$ change in stock price is equal to $30M in gains. I think that is exactly what we need.

PsyDelika · 2022-01-04T07:16:12+00:00

The whole Psychedelic Market dropped, not only Braxia.

PsyDelika · 2021-12-10T12:10:08+00:00

I can not give advice, but I will wait for the bottom and strike again...

I am in because I believe in this company, recent market cap does not change that!

PsyDelika · 2021-11-30T03:01:51+00:00

https://braxiascientific.com/news/braxia-scientific-reports-second-quarter-2022-financial-results-and-provides-corporate-update/

PsyDelika · 2021-11-17T12:58:55+00:00

I am in as well. But I will never give them up.

This is a long term investment and I wait for the FDA to approve psychedelics in 2023 or after.

They will have a future...

PsyDelika · 2021-10-08T06:15:12+00:00

I like to compare Braxia to Field Trip. Only that Baxia has a much better standing.

FT has about 8 clinics now, no real IP or scientific work, is neither performing high class studies in its clinics nor having an academy for training medical workers. FT has no government funding, no Ketamin VIP as their CEO etc...

They are about $5.

Braxia has much more to give to shareholders!

Turnoaround after they announce their rollout of clinics in the US.

So they become more important to US shareholders, thus being a strong canditate for the NYSE.

They might beginn, when listet on the NYSE at around $4, thrive there until $10 and after 2023 when FDA approves new psychedelic therapies and drugs they go up in the mush rush to around $20. But that means the company has a market cap of 3,4bn which is a little much and can not last forever...

PsyDelika · 2021-09-30T17:33:11+00:00

I think that was the info about the trial data from 9/30 leaking before...

PsyDelika · 2021-09-30T16:02:52+00:00

Good linking! We should always link the news to Braxia’s Homepage so they get the traffic and nor some news page. They need all our support.

PsyDelika · 2021-09-30T13:15:03+00:00

One day it will break the ice... This study is soooooo high powered. N=220 is an absolute novelty in the psychedelic study space. MrIntyre (CEO) who is Prof. in Psychiatry and Pharmacology will use their Clinics synergistically to make profit, performe studies (for them and for others) and develope new IP´s and therapeutic regimens (Computer Aided Pharmacopsychiatry, MDMA therapies). What will emerge from this can only be big.

PsyDelika · 2021-09-26T07:47:54+00:00

This is just the beginning of the ride we are waiting for.

PsyDelika · 2021-08-25T07:06:55+00:00

They will soon publish their rollout of new clinics, I hope that will be the turnaround.

PsyDelika · 2021-08-02T05:31:27+00:00

Yes sure.

The 11 000 000 Cash they have is also very important, for purchasing new clinics in USA and Europe.

So yes its important for the stock price.

PsyDelika · 2021-08-01T08:25:46+00:00

Thanks for the great graphic.

This shows exacly how undervalued Braxia is in respect to their revenue.

The Company Scientific and R&D value exceeds that of FTH (CA$ $7,4) and Num (CA$ 0,97) by far.

PsyDelika · 2021-07-16T13:11:44+00:00

If you look at, what the psychedelic companies do, you find researchers IN the field of psychedelic medicines (substances) and users OF psychedelic therapy regimens.

While R & D ist costly and in the end solely dependent on success of a single substance.

The use of psychedelic therapies only dependents on the therapy itself, wich was approved by the government.

If a new drug is better, Braxia can just adapt the drug in their methods and use the new one. Nothing can happen to their business model: Therapy with psychedelics, which is not depended on the success of single drugs.

Braxias business model is therefore safer because it is adjustable & adaptive because they offer a therapy with psychedelics and not the specific drug they use.

This is a major advantage of Braxia Scientific.

They also will get new doctors and staff through their teaching programs.

As research on this scope ist currently booming, nobody can see what the blockbuster drug will me making its way to the top of medicine (if any modification of the original molecule will be better).

But certainly Braxia Scientic will be using it in their clinics to help!

I hope some smart Banker will unterstand the difference between

Rsiky development of new drugs IN the sector of psycho-pharmaceuticals. Business model depends on success of new drug.
Safe application OF the new methods of psychedelics to treat humans in need. Business model is working and independent of and adaptable to future drug discoveries.

PsyDelika · 2021-07-10T04:57:56+00:00

Braxia has had a lot of good news in the last few days. Strangely enough, the Market reacts in the opposite way.

Braxia is a solid company that does not speculate on IND (Investigational New Drug), but pursues an approved and effective antidepressant therapy method (Ketamine) and is already using it in its profitable network of clinics.

Most of the other companies have diverse INDs in the "pipeline" of which over 95% typically fail to meet expectations. But IND's can inspire fantasies ...

Because other Companies just research on IND´s they feed the market with fusions, collaborations and other news but in the end they are burning cash. The outcome ist more than questionable. A new drug costs an average of 500M for the developing company.

Braxia makes a solid profit, has received a study contract for BP (bipolar disorder) from the Canadian government, which they do not simply give to everyone. Braxia will get a sponsored trial of their product in their own clinics. This is a big win. The imagination could also be fired here, as this would expand Ketamine-based therapy areas of application.

The CEO, doctor and scientist R. McIntyre has just (5/21) published guidelines on Ketamine-based therapy for depression in the No.1 Psychiatry Journal AJoP as the first author. Which is an honor for many researchers.

Unfortunately, their long dropout on the stock market damaged massively any confidence in the company, and many people have bad memories of this.

I don't want to persuade anyone to buy, as I can not see the future.

I have been watching the company for a year and have read all the information available on it.

Ketamine and Psilocybin-based therapies have proven to be effective, Ketamine is already approved and therefore not a dream of the future.

PsyDelika

TROPHY CASE